<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628392</url>
  </required_header>
  <id_info>
    <org_study_id>DS8500-A-J203</org_study_id>
    <nct_id>NCT02628392</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Dose Finding Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the study is to evaluate the efficacy, safety, and dose of DS-8500a
      compared with placebo in patients with type 2 diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objectives of the study is to evaluate the efficacy, safety, and dose of DS-8500a
      compared with placebo in patients with type 2 diabetes mellitus after a 12-week oral
      administration of DS-8500a at 25, 50, or 75 mg in a double-blind, parallel-group comparison
      study. In addition, the clinical positioning of DS-8500a relative to an existing drug will be
      investigated using sitagliptin as a comparator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in HbA1c</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
    <description>HbA1c = glycated hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in HbA1c</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HbA1c</measure>
    <time_frame>baseline (Day -1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of subjects with HbA1c &lt;7.0</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
    <description>proportion of subjects who achieve HbA1c &lt;7.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma glucose</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in plasma glucose</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC derived from plasma glucose</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
    <description>change in pharmacodynamics profile consists of Area Under Curve (AUC), Concentration maximum (Cmax), Time of maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC derived from plasma glucose</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
    <description>pharmacodynamics profile consists of AUC, Cmax, Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum insulin</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h serum insulin</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in serum insulin</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h serum insulin</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in proinsulin</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h proinsulin</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in proinsulin</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h proinsulin</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in C-peptide</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h C-peptide</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in C-peptide</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h C-peptide</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in PYY</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
    <description>PYY = peptide YY</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h PYY</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in PYY</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h PYY</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total GLP-1</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
    <description>GLP-1 = Glucagon-Like Peptide-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total AUC 0-3h GLP-1</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total GLP-1</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h total GLP-1</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in active GLP-1</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h active GLP-1</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in active GLP-1</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h active GLP-1</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total GIP</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
    <description>GIP = Gastric Inhibitory Polypeptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h total GIP</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total GIP</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h total GIP</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glucagon</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h glucagon</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in glucagon</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h glucagon</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in 1,5 AG</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
    <description>1,5 AG = 1,5 anhydrogucitol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h 1,5 AG</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in 1,5 AG</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in AUC 0-3h 1,5 AG</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in total cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HDL cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 2</time_frame>
    <description>HDL = high density lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HDL cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HDL cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in HDL cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LDL cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 2</time_frame>
    <description>LDL = low density lipoprotein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LDL cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LDL cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in LDL cholesterol</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in triglyceride</measure>
    <time_frame>baseline (Day -1) to Week 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in triglyceride</measure>
    <time_frame>baseline (Day -1) to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in triglyceride</measure>
    <time_frame>baseline (Day -1) to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in triglyceride</measure>
    <time_frame>baseline (Day -1) to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">368</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DS-8500a 25 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-8500a 25 mg tablet once daily (QD), orally, for up to 12 weeks, and matching sitagliptin placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-8500a 50 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-8500a 50 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS-8500a 75 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DS-8500a 75 mg QD tablet, orally, once daily for up to 12 weeks, and matching sitagliptin placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo tablet and placebo capsule, orally, once daily for up to 12 weeks to match DS-8500a and sitagliptin, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capsule, orally, once daily for up to 12 weeks and matching DS-8500 placebo tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-8500a</intervention_name>
    <description>DS-8500a tablets 25mg, 50mg, 75mg</description>
    <arm_group_label>DS-8500a 25 mg QD</arm_group_label>
    <arm_group_label>DS-8500a 50 mg QD</arm_group_label>
    <arm_group_label>DS-8500a 75 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>capsules</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching DS-8500a tablets and sitagliptin capsules</description>
    <arm_group_label>DS-8500a 25 mg QD</arm_group_label>
    <arm_group_label>DS-8500a 50 mg QD</arm_group_label>
    <arm_group_label>DS-8500a 75 mg QD</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged ≥ 20 years at the time of informed consent

          -  Japanese patients with type 2 diabetes

          -  Patients who have HbA1c ≥ 7.0% and &lt; 10.0%

        Exclusion Criteria:

          -  Patients with type 1 diabetes mellitus or with a history of diabetic coma, precoma, or
             ketoacidosis

          -  Patients receiving or requiring treatment with insulin

          -  Patients with a body mass index (BMI) of &lt; 18.5 kg/m2 or ≥ 35.0 kg/m2

          -  Patients with clinically evident renal impairment (estimated glomerular filtration
             rate [eGFR] of &lt; 45 mL/min per 1.73 m2) or clinically significant renal disease

          -  Patients with fasting plasma glucose ≥ 240 mg/dL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Heishinkai Medical Group Incorporated OCROM Clinic</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Adult</keyword>
  <keyword>Developmental Phase II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

